Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00098475 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 142 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Study sites revised (138)v142 See this version in full on ClinicalTrials.gov ↗
  2. Re-verified, no change to tracked fieldsv141
  3. Study sites revised (138)v140 See this version in full on ClinicalTrials.gov ↗
  4. Completion date: Oct 22, 2025 to Oct 23, 2026v139
  5. Site details revised at 1 of 138 sitesv138
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites revised (138)v137 See this version in full on ClinicalTrials.gov ↗
  2. Study sites revised (138)v136 See this version in full on ClinicalTrials.gov ↗
  3. Re-verified, no change to tracked fieldsv135
  4. Study sites revised (138)v134 See this version in full on ClinicalTrials.gov ↗
  5. Study sites revised (138)v133 See this version in full on ClinicalTrials.gov ↗
  6. Completion date: Oct 22, 2024 to Oct 22, 2025 Study sites revised (138)v132 Show 1 more changeShow less
    • Study sites revised (138)

    See this version in full on ClinicalTrials.gov ↗

  7. Re-verified, no change to tracked fieldsv131
  8. Study sites revised (138)v130 See this version in full on ClinicalTrials.gov ↗
  9. 2 versions Re-verified since Jun 6, 2024, no change to tracked fieldsv128-v129
  10. Study sites revised (138)v127 See this version in full on ClinicalTrials.gov ↗
  11. Study sites revised (138)v126 See this version in full on ClinicalTrials.gov ↗
  12. Study sites revised (138)v125 See this version in full on ClinicalTrials.gov ↗
  13. Re-verified, no change to tracked fieldsv124
  14. Completion date: Oct 22, 2024 Start date: Oct 26, 2004 to Nov 3, 2004v123 Show 1 more changeShow less
    • Start date: Oct 26, 2004 to Nov 3, 2004
  15. Re-verified, no change to tracked fieldsv122
  16. Study sites revised (138)v121 See this version in full on ClinicalTrials.gov ↗
  17. Re-verified, no change to tracked fieldsv120
  18. Study sites revised (138)v119 See this version in full on ClinicalTrials.gov ↗
  19. Re-verified, no change to tracked fieldsv118
  20. Study sites revised (138)v117 See this version in full on ClinicalTrials.gov ↗
  21. Site details revised at 1 of 138 sitesv116
  22. 3 versions Re-verified since May 7, 2022, no change to tracked fieldsv113-v115
  23. Study sites revised (138)v112 See this version in full on ClinicalTrials.gov ↗
  24. Re-verified, no change to tracked fieldsv111
  25. Study sites revised (138)v110 See this version in full on ClinicalTrials.gov ↗
  26. Study sites revised (138)v109 See this version in full on ClinicalTrials.gov ↗
  27. 2 versions Re-verified since Apr 28, 2021, no change to tracked fieldsv107-v108
  28. Study sites revised (138)v106 See this version in full on ClinicalTrials.gov ↗
  29. Re-verified, no change to tracked fieldsv105
  30. Study sites revised (138)v104 See this version in full on ClinicalTrials.gov ↗
  31. Re-verified, no change to tracked fieldsv103
  32. Study sites revised (138)v102 See this version in full on ClinicalTrials.gov ↗
  33. Study sites revised (138)v101 See this version in full on ClinicalTrials.gov ↗
  34. Study sites revised (138)v100 See this version in full on ClinicalTrials.gov ↗
  35. 2 versions Re-verified since Apr 23, 2020, no change to tracked fieldsv98-v99
  36. Study sites revised (138)v97 See this version in full on ClinicalTrials.gov ↗
  37. Site details revised at 1 of 138 sitesv96
  38. 3 versions Re-verified since Dec 9, 2019, no change to tracked fieldsv93-v95
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This randomized phase III trial studies lenalidomide and low-dose dexamethasone to see how well it works compared to lenalidomide and standard-dose dexamethasone, given with or without thalidomide, in treating patients with multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Lenalidomide and thalidomide may also stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide, thalidomide, and dexamethasone together may kill more cancer cells.
Trial Details
NCT Number NCT00098475
Lead Sponsor National Cancer Institute (NCI)
Conditions DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
Enrollment 452 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov